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Inherited Metabolic Diseases (IMDs) are rare diseases caused by genetic defects in
biochemical pathways. Earlier diagnosis and advances in treatment have improved the
life expectancy of IMD patients over the last decades, with the majority of patients now
surviving beyond the age of 20. This has created a new challenge: as they grow up, the
care of IMD patients’ needs to be transferred from metabolic pediatricians to metabolic
physicians specialized in treating adults, through a process called “transition.” The
purpose of this study was to assess how this transition is managed in Europe: a survey
was sent to all 77 centers of the European Reference Network for Hereditary Metabolic
Disorders (MetabERN) to collect information and to identify unmet needs regarding the
transition process. Data was collected from 63/77 (81%) healthcare providers (HCPs)
from 20 EU countries. Responders were mostly metabolic pediatricians; of these, only
∼40% have received appropriate training in health issues of adolescent metabolic
patients. In most centers (∼67%) there is no designated transition coordinator. About
50% of centers provide a written individualized transition protocol, which is standardized
in just ∼20% of cases. In 77% of centers, pediatricians share a medical summary,
transition letter and emergency plan with the adult team and the patient. According to our
responders, 11% of patients remain under pediatric care throughout their life. The main
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challenges identified by HCPs in managing transition are lack of time and shortage of
adult metabolic physician positions, while the implementations that are most required
for a successful transition include: medical staff dedicated to transition, a transition
coordinator, and specific metabolic training for adult physicians. Our study shows that
the transition process of IMD patients in Europe is far from standardized and in most
cases is inadequate or non-existent. A transition coordinator to facilitate collaboration
between the pediatric and adult healthcare teams should be central to any transition
program. Standardized operating procedures, together with adequate financial resources
and specific training for adult physicians focused on IMDs are the key aspects that
must be improved in the rare metabolic field to establish successful transition processes
in Europe.
Keywords: rare disease, inherited metabolic disease(s), transition process, challenge, adulthood (18 years and
older), continuity of care, adult metabolic patient
INTRODUCTION
Inherited Metabolic Diseases (IMDs) encompass an expanding
and comprehensive group of rare diseases caused by inherited
defects in various biochemical pathways. Currently, IMDs
include more than 1,400 different genetic diseases (1) that
can be classified into 130 biochemical groups according to
the underlying metabolic pathway (2). The first symptoms of
IMDs are often non-specific and overlap with more common
disorders, which delays diagnosis and frequently results in organ
dysfunction or failure. Although the individual incidence is low
(from 1 in 10,000 to 1 in 1 million), the cumulative incidence
of all IMDs is high, ranging from 1 in 800 to 1 in 2,500 new-
borns (3–8).
Clinical presentation and course of IMDs are variable,
spanning from acute life-threatening metabolic decompensation
in the new-born period (e.g., hyperammonemic encephalopathy)
to a slowly progressive disease with initial symptoms manifesting
only in adulthood (9). Given the progressive nature of IMDs,
early diagnosis and treatment initiation are extremely important,
as this can slow down or even halt the progression of the
disease. In addition, because of the variability and complexity
of IMDs, highly specialized, experienced, and coordinated
multidisciplinary teams are required in order to minimize
negative health effects and to sustain patients’ quality of life.
Earlier diagnosis and advances in treatment have much
improved the prognosis and life expectancy of IMDs over the
last decades, meaning that more than 90% of rare metabolic
patients will survive beyond the age of 20 years (10, 11).
Moreover, the expanded use of next generation sequencing both
widens the phenotypic spectrum within known diseases and
reveals new IMDs. However, the increased survival has created
a number of new issues and challenges: the development of long-
term age-related complications, the metabolic progression of the
underlying condition, and the lack of data on the natural course
Abbreviations: AOA, amino and organic acids related disorders; C-FAO,
carbohydrate, fatty acid oxidation and ketone bodies disorders; HCP, healthcare
provider; IMD, inherited metabolic disease; TPWG, transition project working
group; SNW, subnetwork; WP, work package.
of the disease. These new challenges require the care of adolescent
IMD patients being transferred from metabolic pediatricians
to metabolic physicians specialized in treating adults to an
increasing extent, including the development and coordination
of a multidisciplinary team for each individual IMD (12). An
adult metabolic team is defined as a core multidisciplinary group
consisting of the following health professions: adult physician,
specialized nurse and/or patient coordinator, metabolic dietician,
and with access to other sub-specialists.
The transition process is critical to ensure that adolescent
patients with IMDs obtain the best quality of life possible as
adults. Also, patients and families need to become empowered
and take full responsibility of their disease. To this end, an
appropriate and gradual transition program is pivotal: patients
need to be informed and accompanied step-by-step as they
gradually switch from a pediatric care in which doctors and
caregivers are responsible for the patient—from organizing
medical visits to buying medications—to an adult care in which
the patient is aware of all the precautions and treatments
to manage her/his condition (under control) and avoid
deterioration. Only through a successful and gradual transition
program will an IMD patient become fully independent and
capable of taking life-long care of her/his health (13).
Transitional care has been defined as “the purposeful, planned
movement of adolescents and young adults with chronic physical
and medical conditions from child-centered to adult-oriented
health care systems” (14). But up to now little has been
done to ensure that transition in IMDs is performed in a
formalized, standardized, and authoritative manner. Although
current literature on transition for chronic diseases in general
is quite extensive (15–17), for IMDs only a few centers have
created specific transition guidelines (12, 18, 19). In addition,
an overview of the different transition practices and challenges
in Europe has never been attempted. The collection of these
important data can serve as a starting point for common
European transition best practice recommendations.
The European Reference Network for Hereditary Metabolic
Disorders (MetabERN), established in 2017, connects centers
specialized in rare metabolic diseases at EU level; it represents
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77 healthcare providers (HCPs) from 23 EU Member States
and 44 patient organizations. It is also endorsed by the Society
for the Inborn Errors of Metabolism (SSIEM). Overall, the
network follows almost 33,000 IMD patients (16,586 adults and
16,277 pediatric patients as of November 2020). MetabERN is
organized in nine work packages (WP) and in seven subnetworks
(SNW), each SNW being specific for the metabolic defects
and/or pathways involved in the disease (for details please
refer to https://metab.ern-net.eu). TheWP9, representing patient
empowerment, has highlighted the need to take urgent care of the
transition process. In 2019, MetabERN and SSIEM organized a
webinar in which four MetabERN centers presented their own
program on transition. Then, in the context of the WP4 on
Guidelines, Care Pathways and Standardization for Medical Care
and Transition, MetabERN established the Transition Project
Working Group (TPWG), which is led by referral experts in the
field in collaboration with the associations of patients.
As a first step in its activities, the TPWG has investigated
how the transition process is currently organized in European
metabolic centers, in particular what transition programs
currently exist, whether there is any reimbursement for
metabolic patients available, and how the transition process
could be supported further to facilitate smooth transition for
metabolic patients.
For this purpose, a survey was created and sent to all
the MetabERN centers to collect information and to identify
unmet needs. The survey covered not only medical, but also
organizational, structural, social, administrative and educational
issues in order to explore and assess potential difficulties in the
organization of an efficient transition process from the point of
view of physicians dealing with patients with IMDs. This initial
overview of the current status of transition in Europe is essential
to raise awareness on the issue at a national and European level.
MATERIALS AND METHODS
The Survey Monkey platform was used to design the survey
and collect the data. Invitations with the link to access the
platform were sent via email to all 77 MetabERN centers in
23 EU countries. The survey included 34 questions aimed at
gathering information on the status of the transition process, its
organization and the associated difficulties and needs from the
perspective of HCPs (see Supplementary Material for full list
of questions). The survey included multiple choice questions,
with the possibility to write additional text under the option
“Other” when available; only in the last question participants
were asked to add any relevant comment as free text (see
Supplemental Material). Members of the TPWG prepared the
survey in collaboration with adult IMD patients and patients
associations (see section Acknowledgments). The survey was
active for 20 months, from 1st October 2018 to 1st May
2020. All participants (see section Acknowledgments) gave
their consent for data collection and publication. Data was
extracted and descriptive statistical analysis was performed using
Microsoft Excel.
RESULTS
Data was collected from 63/77 (81%) HCPs from 20 EU countries
(Table 1). Responders were mostly metabolic pediatricians
(65.1% pediatric vs. 11.1% adult metabolic physicians; 23.8%
clinical geneticists and other specialties), with representatives
covering all disease SNW, but dominated by the largest disease
entities: lysosomal storage disorders (LSD; 87.1%), amino and
organic acids related disorders (AOA; 83.9%), and carbohydrate,
fatty acid oxidation and ketone bodies disorders (C-FAO; 80.7%)
(Table 1).
Of the responding centers, 6.4% are dedicated exclusively
to adults, 84.1% of centers follow both adult and pediatric
patients, while 9.5% are pediatric only (Table 1). Overall, almost
all responding centers follow adult patients (93.7%), and the
majority of these have a separate adult metabolic team. However,
in only 30.7% of cases is the adult metabolic team available for
all metabolic conditions (Table 1). The main reasons identified
for the centers not to have an adult team include: (i) no interest
in the metabolic field from adult physicians (34.7%); (ii) no
existing position (30.8%); (iii) lack of specialty adult training in
the country (30.8%); and (iv) preference of patient/family to be
followed by the pediatric team (30.8%) (Table 1).
In centers with existing transition programs, for over half the
cases (52.4%) transition starts at 18 years of age. Consequently,
the process is mostly finalized after the age of 18 (57.1 vs. 21.4%
between 16 and 18 years of age), while 10.7% of patients never
transition because they remain under pediatric care throughout
their life (Table 1). Of the doctors involved in the transition
process, the majority of the respondents (87.7%) discuss the
transition issue with the adolescent patients and parents, but
<50% have a separate consultation with the child/adolescent.
Medical specialities involved in the medical care of adult
metabolic patients are mainly internists (50%), followed by
clinical geneticists and cardiologists (15.6% each) (Table 2).
In the majority of centers (80.7%) the adult patients are
followed also by other specialists, mainly neurologists (77.8%),
cardiologists (64.8%), nephrologists (61.1%), and nutritionists
(59.3%) (Table 2). Importantly, it should be noted that among
cardiologists and nephrologists participating in the survey, also
pediatricians were represented, further increasing the percentage
of pediatricians caring for adult patients with an IMD. In most
centers there is no designated transition coordinator (69.5%)
and no dedicated physician in charge of the transition on the
adult side that collects and summarizes information from each
sub-specialist (62.1%) (Table 2).
Almost half of the centers (48.2%) provide a written
individualized transition protocol, which is standardized in
nearly 20% of cases (Table 3). In the majority of centers (63.4%)
no patient organization has been involved in the development
of the transition plan (Table 3). In almost 77% of centers
pediatricians share a medical summary, transition letter and
an emergency plan (if applicable) with the adult team and the
patient (Table 3). This document contains information such as
medications and relative dosage, comorbidities, a short summary
of the disease and precautions, an emergency regime, a nutrition
plan when healthy, and the last blood test results (Table 3).
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TABLE 1 | Characteristics of the responders and the relative centers.
Category n (%)
Profession:
Metabolic pediatrician 41/63 (65.1)
Adult metabolic physician 7/63 (11.1)
Clinical geneticist 3/63 (4.8)
Other (neurologist, cardiologist, psychologist, genetic counselor,
clinical biochemist, internal medicine/endocrinology/diabetes
specialist)
12/63 (19)









Adult and pediatric center 53/63 (84.1)
Pediatric center only 6/63 (9.5)
Adult center only 4/63 (6.4)
Center following adult patients with IMDs:
Yes 59/63 (93.7)
No 4/63 (6.4)
Center with separate adult metabolic team:
Yes, for all kinds of metabolic conditions 19/62 (30.7)
Yes, for the majority of metabolic conditions 12/62 (19.4)
Yes, for selected groups of metabolic conditions 12/62 (19.4)
No, pediatric team follows patients life-long 5/62 (8.1)
Reasons for not having an adult metabolic team:
Lack of interest in IMDs among adult physicians 9/26 (34.6)
Patient/caregiver’s preference to be followed by pediatric
metabolic department
8/26 (30.8)
Lack of special training for adult physicians in metabolic
diseases in the country
8/26 (30.8)
No existing position/vacancy for adult metabolic diseases at the
center
8/26 (30.8)
Lack of financial support 5/26 (19.2)
Lack of extra reimbursement for adult complex metabolic
patients
5/26 (19.2)
Lack of adult physicians willing to be involved 4/26 (15.4)
Other (historically, adult IMD patients have been taken care in
the pediatric hospital; difficulties in getting more salaries for adult
physicians; smooth transition by joint follow-up with both adult
and pediatric physician until the patient agrees to be followed by
the internist)
14/26 (53.9)
Age at which transition process starts:
18 years of age 33/63 (52.4)
16 years of age 12/63 (19)
20 years of age 2/63 (3.2)
Other (at 10 or 14 years of age; after 18 years of age or later;
from 16 to 28 years of age, start discussion on transition from
age 12; no transition process)
16/63 (25.4)
(Continued)
TABLE 1 | Continued
Category n (%)
Age at which transition process is finalized:
>18 years of age 32/56 (57.1)
16–18 years of age 12/56 (21.4)
Never, because the patient remains under pediatric care
throughout his/her life
6/56 (10.7)
14–16 years of age 0/56 (0)
12–14 years of age 0/56 (0)
Never, because the patient is transferred to an adult clinic
without any preparation
0/56 (0)
Other (for older patients the transition is finalizing now,
regardless of age, while for Fabry and other patients it is finalized
at 16 years of age; depends on the disease: some patients
remain at least in part managed by pediatricians)
6/56 (10.7)
AOA, Amino and organic acids-related disorders; PM-MD, Disorder of pyruvate
metabolism, Krebs cycle defects, mitochondrial oxidative phosphorylation disorders,
disorders of thiamine transport andmetabolism; C-FAO, carbohydrate, fatty acid oxidation
and ketone bodies disorders; LSD, lysosomal storage disorders; PD, peroxisomal
disorders; CDG, congenital disorders of glycosylation and disorders of intracellular
trafficking; NOMS, disorders of neuromodulators and other small molecules.
Among the responding physicians, only 39.7% have received
appropriate training in managing health issues in adolescent
metabolic patients, while the others acquired the necessary
knowledge mainly through courses and internships in metabolic
centers (Table 4).
The main challenges of HCPs in managing the transition
process are lack of time (49.2%) and shortage of adult metabolic
physician positions (44.1%) (Table 4). This is reflected in the
implementations that, according to the responders, are most
required for a successful transition: medical staff dedicated to
transition (51.7%), a transition coordinator (45%), and specific
metabolic training for adult physicians (43.3%) (Table 4). Lastly,
90% of responders report the absence of any financial support for
transition programs (Table 4).
DISCUSSION
This survey provides the first European report on the status
of the transition process in rare metabolic diseases from the
HCPs perspective. With 63 centers responding from 20 EU
countries, our results may provide a representative overview of
the current situation in European centers of excellence, selected
for their expertise in metabolic diseases. The pediatric specialty
was the most prevalent responder group in our survey, reflecting
predominantly the pediatricians’ point of view in the transition
process. At the same time, our surveys show a large disproportion
between the medical specialties looking after IMD patients. This
underlines the multisystemic nature of IMDs and the peculiar
need of affected patients to be followed by multiple professionals,
who should interact and collaborate with one another within a
well-defined multisystemic approach framework. Unfortunately,
in a real world situation patients are seen by different specialists
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TABLE 2 | Specialties involved in the care of adult IMD patients and their
transition.
Category n (%)
Specialty of the physician taking care of adult IMD patients:
Internist 16/32 (50)
Clinical geneticist 5/32 (15.6)
Cardiologist 5/32 (15.6)
Neurologist 4/32 (12.5)





Social worker 2/32 (6.3)
Surgeon 1/32 (3.1)
Clinical trial technician 1/32 (3.1)
Coordinator/secretary 1/32 (3.1)
ICU and anesthetist 1/32 (3.1)
Gastroenterologist 1/32 (3.1)
Genetic counselor 1/32 (3.1)
Medical biochemist 1/32 (3.1)
Neuro-pediatrician 1/32 (3.1)
Otorhynolaryngologist 1/32 (3.1)
Palliative care 1/32 (3.1)
Pharmacist 1/32 (3.1)
Physical and rehabilitation medicine 1/32 (3.1)
Psychologist 1/32 (3.1)
Pneumologist 1/32 (3.1)







School educator 0/32 (0)
Stomatologist 0/32 (0)
Other (endocrinologist, nephrologist, pediatrician, metabolic
physician)
8/32 (25)










Laboratory geneticist 17/54 (31.5)
Rehabilitation specialist 14/54 (25.9)
Gastroenterologist 12/54 (22.2)
General internal medicine 12/54 (22.2)
(Continued)




Designated transition coordinator at the center:
Yes 18/59 (30.5)
No 41/59 (69.5)




that rarely know or communicate with each other, resulting in a
fragmented, uncoordinated and suboptimal care.
Here we show that most HCPs discuss transition with the
family and share a medical summary with the adult physician and
the patient. In most cases, this summary is not standardized and
includes a short description of the disease, its precautions
and comorbidities, type and dosage of medications, a detailed
emergency regime, a nutrition plan, and the latest blood test
results. Despite decades of increasing knowledge regarding the
importance of a properly structured transition for later health
outcomes (20, 21), our survey still demonstrates unmet needs and
overall slow acquisition of the mandatory aspects for a successful
transition for rare metabolic patients, their families and adult
physicians in Europe.
In most centers a transition coordinator is missing and the
process is fragmented or even non-existent, to a point where
about 10% of patients never transition and stay under pediatric
care all their life. In this context, the presence of a transition
coordinator is a major factor for a successful transition program,
as it ensures that adult care teams are aware of, and prepared
for, the management of rare conditions and their peculiarities.
The coordinator schedules the transition meetings, collects and
updates all the necessary documentations, and ensures that all
appropriate specialists and social professionals are present during
the transition visits. Despite these differences, the transition
coordinator should have defined duties to ensure the highest
standards and success of the transition process. Our survey
identified that the appointment of a transition coordinator is
necessary, which calls for immediate action from healthcare
organizations and policy makers to improve the transition
process across Europe. The need for this new administrative role
has also been identified by De Castro et al. (22).
Another main finding in our study is the shortage of
physicians specialized in the adult care of IMDs. In fact,
only 11% of the respondents to the survey were adult
IMD professionals and most centers stated that an adult
team was only available for a subset of metabolic diseases.
In this context, the lack of specific metabolic training for
adult physicians regarding adolescent health issues must be
emphasized, as this is a key factor for implementing a
successful transition program. Education of adult specialists
in IMDs is important for a number of reasons: not only do
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TABLE 3 | Information exchanged among physicians for/during transition.
Category n (%)
Written individualized plan/protocol/letter for transition provided:
No, no particular documents are provided other than
the medical record itself
22/56 (39.3)
Yes, a written individualized document for transition is
provided, but it is not standardized
15/56 (26.8)
Yes, the hospital has a standard operating procedure
for transition
6/56 (10.7)
Yes, a written standardized individualized protocol for
each patient is provided
5/56 (8.9)
Yes, a document for transition is provided, but without
knowing which physician to address it to if the patient
will be followed at another hospital
1/56 (1.8)
No, but an unwritten transition agreement/procedure is
arranged with the patient
1/56 (1.8)
Other (ongoing protocol setup, summary letter, full
documentation)
6/56 (10.7)
Relevant patient organization(s) involved in the
development of a standard procedure for transition,




Pediatric team sharing medical summary, transition




Other (emergency plan only, hospital discharge
summary, in the making)
5/56 (8.9)
Information included in the medical summary:
Medications 45/49 (91.8)
Short summary of disease and precautions 44/49 (89.8)
Updated list of medications and dosages 44/49 (89.8)
Comorbidities 42/49 (85.7)
Detailed emergency regime 39/49 (79.6)
Last blood test results 38/49 (77.6)
Nutritional plan when healthy 36/49 (73.5)
Medications to avoid 29/49 (59.2)
Suggested blood tests when admitted to hospital 28/49 (57.1)
Anesthesia precautions 26/49 (53.1)
Surgery preparation instructions 24/49 (49)
Other (pregnancy precautions, recurrence risk,
emergency regime, full history radiological images,
psychological tests report, special needs)
13/49 (26.5)
an increasing proportion of pediatric patients survive with
more complex disorders and with neurocognitive disabilities,
but a greater number of IMDs presenting in adulthood
are being diagnosed in the genomic era. As a part of
education and optimization of the transition process, it
is important to develop cooperation and trust between
pediatricians and adult physicians (22). This will facilitate a
more harmonious and less stressful transition process for the
IMD patients.
TABLE 4 | Shortcomings, challenges and needs related to transition.
Category n (%)
Members of team looking after adolescent patients with formal
training in health issues in adolescent IMD patients:
Yes 23/58 (39.7)
No 31/58 (53.5)
Other (SSIEM courses and conferences, only for some IMD, only
for general health issues in adolescents)
4/58 (6.9)
Informal methods used to acquire knowledge on treating
adolescent IMD patients:
Course 13/36 (36.1)
Placement in metabolic center 13/36 (36.1)
Non-recognized education program 11/36 (30.6)
Fellowship 9/36 (25)
Other (personal study, clinical practice, part of another
specialization, prolonged work with IEM, cooperative interaction)
12 (33.3)
Most difficult challenges in managing the transition process:
Lack of time 29/59 (49.2)
Lack of adult metabolic physician positions/vacancies 26/59 (44.1)
Knowledge gaps on the topic amongst medical staff 17/59 (28.9)
Lack of reimbursement 14/59 (23.8)
Lack of interest 9/59 (15.3)
Poor communication between pediatric and adult centers 7/59 (11.9)
Other (lack of pediatric metabolic physicians, growing number of
patients, lack of cases manager, metabolic medicine is not
available as specialization, no financial support, no official
metabolic position, few doctors dedicated, low number of
pts/condition and diverse patient population)
17/59 (28.8)
Most needed implementations for a successful transition:
More staff specifically dedicated to transition 31/60 (51.7)
A dedicated transition coordinator 27/60 (45)
Special metabolic training for adult physicians 26/60 (43.3)
Dedicated (or interested) adult physicians 21/60 (35)
Adult metabolic positions 19/60 (31.7)
A transition protocol/standard operating procedure 19/60 (31.7)
A physical space for transition clinics 17/60 28.3)
Other (setup of a transition clinic; adult metabolic clinic; support
by paramedics such as dietitians, psychologists, social workers;
more protocols for adult patients; more pediatricians and
metabolic adult physicians; more time to dedicate to transition)
8/60 (13.3)
Availability of additional financial support for transition clinics:
Yes 3/60 (5)
No 54/60 (90)
Other (information unknown; no transition in place, process for
improvement is ongoing)
3/60 (5)
The SSIEM recently launched a survey to 89 adult specialist
members. Despite the fact that practical clinical experience with
adult IMDs was considered key for their own education in
rare metabolic diseases, most responders (73%) judged their
education as poor or fair. The main message was the need for
formal training opportunities in adults and courses on IMDs
(23). These results were confirmed by our survey, in which only
about 40% of responders reported formal training in health issues
regarding adolescent IMD patients, while informal training such
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as fellowships, short courses, work placement, clinical practice
and personal studies were common. As a result, neither pediatric
nor adult clinicians are prepared to adequately address the
complex developmental challenges that characterize adolescent
metabolic patients. Indeed, our survey indicates that the factors
that are mostly needed by HCPs are: adult physician positions,
a transition coordinator, and specific metabolic training for
adult physicians. The shortage of adult metabolic specialists has
increasingly been revealed by the advancements made over the
last few decades in metabolic diseases. Adult physicians have
historically not been involved in the management of IMDs
because until about 20 years ago 75% of metabolic patients died
before reaching the adult age, resulting in a “skewed population
of providers” (22). Today, thanks to better healthcare, improved
follow-up programs, and more treatments available there is an
increasing number of metabolic patients that reach adulthood. In
this regard, both SSIEM and MetabERN are already organizing
dedicated courses to create and train a new class of professionals,
and in particular adult physicians, with expert knowledge and
practical experience in the long-term care and management of
IMDs. However, additional support is needed from hospital
managements, authorities, and the European Commission to
encourage adult physicians to focus on IMD patients. This will
be important also to overcome another aspect highlighted by our
survey, that is the lack of interest in IMDs by medical students
and/or adult physicians. As rare and complex diseases, IMDs
are not well known and are often overlooked in the medical
community; therefore, more effort is needed to disseminate
information about the challenges and opportunities offered by
the metabolic disease field and thus create novel interest in
this specialty.
Our results show that adult IMD patients are regularly
followed mainly by internists, with the widespread involvement
of other sub-specialists, illustrating the complexity of the
diseases. This is not surprising, as most adults with a chronic
condition demand surveillance by different specialists; however,
this also highlights the fact that healthcare is more fragmented
in adulthood. This might create obstacles in guaranteeing
a continuous and holistic care of adult metabolic patients.
Therefore, it is necessary to create a multidisciplinary team
of HCP specialized in the treatment of adult patients with
IMDs; for example, a team coordinated by an internist
specialist in metabolic diseases. Regarding the type of specialties
following IMD patients, these include mostly neurologists,
cardiologists, nephrologists, orthopedist and nutritionists. This is
not surprising, as it is a reflection of the multi-organ involvement
of IMDs and the importance of a balanced diet to avoid
metabolic decompensation.
The whole process of transition is further complicated by
the lack of standardized programs or specific guidelines shared
across Europe. This is a crucial aspect that needs to be addressed
by institutions and policy makers in order to ensure that the
best possible care—and therefore quality of life—is given not
only to IMD and other rare disease patients, but to all patients
with a chronic condition that arises during childhood. Indeed,
the transition issues that were highlighted with our survey may
be shared by other chronic conditions. As a possible solution
strategy, the optimization of electronic medical records could be
of help.
The lack of financial resources is another aspect that
makes it difficult to implement appropriate transition teams
and programs. In the midst of the current COVID-19
pandemic, which imposed great changes in healthcare funds
and organization, rare diseases must not be forgotten and
specific activities should be put into place to increase awareness
in public institutions and authorities about IMDs and the
transition process.
From the patient perspective, there are significant challenges
to be considered when transitioning from a family-centered,
developmentally-focused, and multidisciplinary pediatric care to
a less supportive adult healthcare system that is often unfamiliar
with rare diseases (13). Among them, there is the resistance and
lack of trust of the patient and his/her family in regard to the adult
team, and the fear of a lack of expertise in the adult specialists.
Indeed, in a recent study on expectations of adolescents with
chronic disorders and their parents, the most important barriers
identified for successful transition were anxiety and lack of
information of the adult healthcare specialist (24). Therefore,
it is important to predispose combined consultations with
the pediatric and adult specialists, to anticipate the exchange
of medical records, and to establish clear communication
strategies, which can be extremely beneficial in mitigating these
difficulties and in making the patient and the caregivers feel
more comfortable and continually cared for at the highest
standards. Better information and education on their disease,
as well as greater active involvement in the decision-making
of their care, may be pivotal to improve patient and family
adherence to and satisfaction with transitioning (22, 25). In this
context, the role of patient associations is important to promote
such measures. In addition, from a patient point of view, the
transition process is multidimensional, involving transitions with
respect to development (adolescent becoming a young adult),
situation (switch from pediatric services to adult health services)
and health–illness (role changes, self-management of a chronic
condition) (25). Due to the heterogeneity of IMDs regarding
organ involvement and disease severity, an interdisciplinary
framework of care should be introduced stepwise to meet
the biopsychosocial needs of early adolescents (11–15 years of
age), late adolescents (16–18 years old), and emerging adults
(18–25 years of age), thereby also differentiating between life-
threating IMDs, IMDs with chronic illness, and IMDs with
severe disabilities and/or severe intellectual impairments (11, 25,
26). Since the current survey did not target patients and their
families, a dedicated survey is necessary to focus on their point
of view.
This study has several limitations. Firstly, it provides only the
MetabERN HCPs’ point of view. More specifically, the majority
of respondents were pediatricians, as they have been the historical
managers of patients with IMD, leaving the adult perspective of
the transition process less represented. Moreover, transition is
a process involving several key players in the center of interest;
therefore, the next survey to complement that of the HCPs should
be targeted at patients and their associations to understand
their point of view and especially to gather information on
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the social and psychological aspects of transition, which seems
even more difficult in patients with multiple disabilities. Our
survey focused on HCPs, which can provide information and
suggestions regarding the more practical and administrative
aspects of the transition process. In fact, no publications exist
on the patient or caretaker point of view and indeed this is
one of the next steps to be taken by MetabERN. Secondly,
due to the design of the survey, we were not able to collect
specific data regarding the percentage of pediatricians that are
involved in the care of adult IMD patients. The majority of
our responders (65%) were pediatricians and at present we
are not able to assess whether other specialists taking care of
adult patients are also pediatricians. Thirdly, specific questions
about the set-up and maintenance of a successful transition
process were missing, so at this stage we cannot provide
exhaustive examples or recommendations on how to improve
the transition where this is difficult. Further work is needed
to propose specific transition recommendations in the field
of IMDs, for example by using templates from hospitals that
have a long experience with transition and have made some
written recommendations, also taking into account the patients’
perspective. Indeed, this is part of the further activities planned
by MetabERN’s TPWG.
The final aim of MetabERN and the TPWG is to collaborate
and share expertise and good practices to develop possible
action guidelines and minimal standard of care. In this way, all
specialists involved in the care of IMD patients, and potentially
in other fields, will have access to guidance and support in
the management of the critical process of transition, which in
turn will aid a successful and efficient transfer from pediatric
to adult care for all patients. This study is the first step in
that direction.
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